REGENERON PHARMACEUTICALS, INC. (REGN) closed fiscal year 2025 with a gross margin of 85.4 % and a net margin of 31.4 %.
REGENERON PHARMACEUTICALS, INC. (REGN) closed fiscal year 2025 with a gross margin of 85.4 % and a net margin of 31.4 %. The same year shows an EBITDA margin of 28.7 % and an EBIT margin of 24.9 %. The free cash flow margin was 28.4 %. Against the previous year the gross margin moved −0.8 pp and the net margin +0.3 pp. Across the period the gross margin ranges between 85.4 % in 2025 and 99.6 % in 2008. The series covers 18 fiscal years, from 2008 to 2025. Margins are expressed as a percentage of net revenue and are derived from the same figures as the income statement, taken from as-reported SEC EDGAR filings, with no restatements or adjustments of our own.
Fiscal year end: December
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin (%) | 99.61 % | 99.56 % | 99.54 % | 99.05 % | 93.91 % | 94.39 % | 95.42 % | 94.11 % | 96.00 % | 96.55 % | 95.38 % | 93.86 % | — | — | 87.18 % | 86.16 % | 86.13 % | 85.35 % |
| EBITDA margin (%) | -31.44 % | -15.79 % | -16.94 % | -39.05 % | 35.88 % | 37.26 % | 31.09 % | 32.33 % | 29.53 % | 37.89 % | 52.13 % | 36.91 % | 44.87 % | 57.45 % | 41.73 % | 34.06 % | 31.50 % | 28.74 % |
| EBIT margin (%) | -36.17 % | -19.54 % | -21.23 % | -46.02 % | 33.20 % | 35.30 % | 29.22 % | 30.51 % | 27.38 % | 35.41 % | 49.25 % | 33.70 % | 42.09 % | 55.67 % | 38.93 % | 30.85 % | 28.10 % | 24.95 % |
| Net margin (%) | -33.18 % | -17.88 % | -22.76 % | -49.74 % | 54.43 % | 19.66 % | 11.99 % | 15.50 % | 18.42 % | 20.41 % | 47.50 % | 32.26 % | 41.35 % | 50.25 % | 35.64 % | 30.14 % | 31.07 % | 31.41 % |
| FCF margin (%) | -51.98 % | -44.10 % | -0.10 % | -44.61 % | -8.99 % | 20.54 % | 14.88 % | 15.91 % | 20.04 % | 17.62 % | 35.21 % | 30.51 % | 23.58 % | 40.63 % | 36.35 % | 29.54 % | 25.80 % | 28.45 % |
